By Patrick Wingrove and Maggie Fick (Reuters) -As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard ...

As Denmark's Novo Nordisk shops for its next CEO to replace Lars Fruergaard Jorgensen, it should look across the Atlantic for a leader deeply entrenched in the United States, by far its largest market ...

Weight loss drugs have become an increasingly popular, but controversial, way of quickly shedding extra pounds over the past ...

Ozempic-maker Novo Nordisk on Friday ousted its CEO Lars Fruergaard Jorgensen over concerns the company is losing its ...

Jørgensen has agreed to stay on while the search for a successor is carried out, and the chair of the Novo Nordisk Foundation ...

Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...

Novo Nordisk announces CEO transition as Lars Fruergaard Jørgensen departs amid Wegovy market share losses to Zepbound and ongoing supply chain disruptions ...

Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

It’s the end of an era at Novo Nordisk as longtime CEO Lars Fruergaard Jørgensen—who recently shepherded the company through ...

For every man who has cut carbs from his diet and dropped 10 pounds, there’s a woman who’s done exactly the same thing ...

The Danish company said Jorgensen is leaving by mutual agreement with the board, though he’ll continue as chief 'for a period ...